top of page
NemaLife YouTube Banner-2.png

NemaLife News

  • Writer's pictureNIH

New Approaches for Incorporating Genetic Diversity into Toxicity Testing

Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimer’s Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed

Our multi-prong approach is expected to de-risk drug failure in mammalian AD models. In summary, we will use a novel NemaLife technology to identify a subset of pharmacological longevity interventions will exert neuroprotection against AD-relevant stresses.

bottom of page